Study of three antibodies in people on hemodialysis
Part of Heart & circulation, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests three study drugs (called monoclonal antibodies) in people with end-stage kidney disease who are on hemodialysis. The goal is to see if these drugs are safe and how they affect your body while you're on dialysis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be on hemodialysis three times a week.
- You must be able to receive heparin (a blood thinner) during dialysis without any issues.
- You must have good vascular access (the site where dialysis needles go in).
- You must have been stable and not hospitalized in the last 30 days.
- You must not have had major bleeding in the past 3 months, and no bleeding disorders like hemophilia or von Willebrand disease.
- You must not be taking blood thinners (like warfarin or DOACs) or dual antiplatelet therapy (like aspirin plus clopidogrel).
- You must not have severe heart failure (NYHA class III or IV) or uncontrolled high blood pressure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how a new drug called CSL300 (clazakizumab) works in the body of people with end-stage kidney disease who are on dialysis. Researchers want to understand if it's safe and how your body processes it.
This trial compares a newer type of dialysis called hemodiafiltration with standard hemodialysis to see if it improves certain health measures in people with end-stage kidney disease. It may help determine which method works better for long-term treatment.
This study tests whether dialysis can be done safely without using heparin (a blood thinner) in people with end-stage kidney disease. If successful, it could reduce the need for blood-thinning medications and their associated risks.
This study tests an experimental drug called KN060, given to people with end-stage kidney disease on dialysis, to see if it is safe and helps with blood clotting. It may be an option if you are on stable dialysis and not at high risk for bleeding.
This trial tests whether adding a special filter called pHA130 to your regular dialysis treatments can better remove certain waste products from your blood and improve your quality of life. It's for people who have been on dialysis for at least 3 months and meet a few health requirements.
This study tests an investigational drug that blocks a protein called ANGPTL3, which may help protect the kidneys in people with type 2 diabetes and diabetic kidney disease. It aims to see if the drug can reduce kidney damage and improve overall health.
Hear when a new End-Stage Kidney Disease (ESKD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.